2025
Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible
Velez F, Rajani R, Malone D, Sun L, Bloudek L, Carter K, Panaccio M, Niklason L. Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible. Journal Of Medical Economics 2025, 28: 323-334. PMID: 39964834, DOI: 10.1080/13696998.2025.2469460.Peer-Reviewed Original ResearchConceptsConduit infectionAutologous veinTissue engineered vesselHarvest site infectionBudget impactTrauma centerSurgical re-interventionOperating roomLevel I trauma centerGraft infectionBudget impact modelRe-interventionComplication rateSite infectionVein repairGraft typeClinical studiesProsthetic graftsParameter uncertaintiesPost-discharge costsArterial traumaPROOVIT registryTrauma repairOR timeInfection
2024
Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Shoukat A, Bawden C, Röst G, LeBlanc J, Galvani A, Langley J, Moghadas S. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine 2024, 42: 1768-1776. PMID: 38368226, DOI: 10.1016/j.vaccine.2024.02.041.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsLong-term care homesCommunity-dwelling older adultsCanadian Immunization Research NetworkIncremental cost-effectiveness ratio valuesResidents of long-term care homesRSV diseaseOlder adultsBurden of RSV diseaseRespiratory syncytial virus diseaseNo-vaccination scenarioRSV-related hospitalisationNo vaccinesRespiratory syncytial virusVaccination programBudget impactSocietal perspectiveCost-effectiveness ratioReduction of hospitalizationInfluenza vaccineRSV seasonSyncytial virusHealth benefitsAnalysis of vaccination
2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategies
2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volumeEconomic Evaluation Design within the HEAL Prevention Cooperative
Dunlap LJ, Kuklinski MR, Cowell A, McCollister KE, Bowser DM, Campbell M, Fernandes CF, Kemburu P, Livingston BJ, Prosser LA, Rao V, Smart R, Yilmazer T. Economic Evaluation Design within the HEAL Prevention Cooperative. Prevention Science 2022, 24: 50-60. PMID: 35947282, PMCID: PMC9364296, DOI: 10.1007/s11121-022-01400-5.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid misuseUse disordersYoung adultsPrevention interventionsOpioid crisisAddiction Long-term (HEAL) InitiativeSubstance use prevention programmingUrgent public health problemEffective prevention interventionsPublic health problemOlder adolescentsEconomic evaluation designOpioid misuse initiationEconomic evaluationHealth problemsPreventive interventionsBudget impactIntervention implementation costsDisordersInterventionNational InstituteEconomic evidencePrevention programmingAdults
2020
Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States
Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. JAMA Network Open 2020, 3: e2016818. PMID: 32735339, PMCID: PMC7395236, DOI: 10.1001/jamanetworkopen.2020.16818.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSymptom-based screeningTrue-positive resultsCost-effectiveness analysisHypothetical cohortCumulative infectionsAsymptomatic SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Safe returnCoronavirus disease 2019 (COVID-19) pandemicSyndrome coronavirus 2Case fatality riskCOVID-19 infectionDisease 2019 pandemicResidential college campusCoronavirus 2Additional infectionsMAIN OUTCOMEBudget impactInfectionBehavioral interventionsCohortFall 2020 semester
2019
Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis
Smith KC, Losina E, Messier SP, Hunter DJ, Chen AT, Katz JN, Paltiel AD. Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. ACR Open Rheumatology 2019, 2: 26-36. PMID: 31943972, PMCID: PMC6957917, DOI: 10.1002/acr2.11090.Peer-Reviewed Original ResearchKnee osteoarthritisMedicare plansIntensive dietKnee OA treatmentIncidence of comorbiditiesCommercial insurance plansHealth promotion interventionsMedicare-eligible individualsOsteoarthritis Policy ModelTotal knee replacementCommercial plansObese patientsOpioid useMore patientsExercise programArthritis trialsKnee replacementMedicare Advantage plansOsteoarthritisOA treatmentBudget impactMedical expendituresInsurance plansPatientsDietRapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector
Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector. PLOS ONE 2019, 14: e0218890. PMID: 31265470, PMCID: PMC6605662, DOI: 10.1371/journal.pone.0218890.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLife expectancySmear microscopyXpert MTB/RIFHIV-negative adultsPeripheral healthcare settingsMTB/RIFPrimary healthcare facilitiesSputum smear microscopyCost-effectiveness ratioCost-effectiveness analysisPresumptive tuberculosisTB diagnosisTB prevalenceTruenatMicroscopy centresXpertBudget impactRifampicin resistanceDiagnostic strategiesTuberculosisTB detectionHealthcare settingsDiagnostic sensitivityNovel molecular assayCost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2018
2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector
Lee D, Kumarasamy N, Resch S, Sivaramakrishnan G, Mayer K, Tripathy S, Paltiel A, Freedberg K, Reddy K. 2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector. Open Forum Infectious Diseases 2018, 5: s582-s582. PMCID: PMC6254532, DOI: 10.1093/ofid/ofy210.1656.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioPublic healthcare facilitiesLife expectancyXpert MTB/RIFHIV-negative patientsPeripheral healthcare settingsHealthcare facilitiesBudgetary impact analysisMTB/RIFDiagnostic test costsSputum smear microscopyCost-effectiveness ratioMulti-way sensitivity analysesTB outcomesTB diagnosisPoint of careTruenatSmear microscopyXpertBudget impactTuberculosis diagnosticsDiagnostic strategiesHealthcare expendituresHealthcare settingsRifampin resistance
2016
Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases
Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases. Hepatology 2016, 64: 1331-1342. PMID: 26926906, DOI: 10.1002/hep.28527.Peer-Reviewed Original ResearchConceptsHealth economic evaluationsEconomic evaluationAlternative health care interventionsDecision analytical modelingCost-effectiveness analysisHealth economic analysisDecision analytical modelDecision analytic modelHealth care interventionsEconomic analysisEconomic sustainabilityHealth care costsBudget impactDecision makersMedical innovationCare costsSocioeconomic contextSustainabilityCare interventionsFair accessMarketMakersAnalytical toolsInnovationCurrent contextLaboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategies
2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival rate
2010
Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. Value In Health 2010, 13: 893-902. PMID: 20950323, PMCID: PMC2999642, DOI: 10.1111/j.1524-4733.2010.00763.x.Peer-Reviewed Original ResearchConceptsHIV screeningEarly treatment goalsNew HIV casesFrequency of screeningBudget impact analysisTotal budget increasesHIV careAnnual incidenceHIV casesHIV prevalenceCDC estimatesUS CentersTreatment goalsBudget impactTreatment programDisease controlHIVTest characteristicsTreatment costsFinancial burdenCareScreeningSmall proportionProgram savingsFund care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply